Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan-Mar;16(1):3-7.
doi: 10.4103/1450-1147.198237.

68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review

Jose M Oliveira  1 , Catarina Gomes  2 , Diogo B Faria  3 , Tiago S Vieira  1 , Fernando A Silva  1 , Joana Vale  3 , Francisco L Pimentel  4
Affiliations
Review

68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review

Jose M Oliveira et al. World J Nucl Med. 2017 Jan-Mar.

Abstract

The 68Ga-prostate-specific membrane antigen ( 68Ga-PSMA) has been recently developed to be used, as a ligand, in positron emission tomography/computed tomography (PET/CT) prostate cancer imaging, to detect prostate disease. The main objective of this review was to collect data and findings from other studies and articles to assess, theoretically, if 68GA-PSMA PET/CT is a more appropriate prostate cancer diagnostic technique in comparison with others available such as CT, 18F-fluoro-2-deoxyglucose PET/CT, or 18F-fluoromethylcholine ( 18F-choline) PET/CT. For that purpose, PubMed, the online scientific articles' database, was consulted where the keywords "PSMA" and "PET" were used to find relevant articles. The clinicaltrials.gov, clinical trials' database, was also consulted where the keywords "68Ga-PSMA" and "prostate" were used to search clinical trials. Based on the reviewed scientific literature, several studies were conducted to assess and compare the 68Ga-PSMA PET/CT detection rate in prostate cancer with other available techniques. One of those studies, conducted by Giesel et al., concluded, within study sample, that 75% of patients with lymph nodes detected by 68Ga-PSMA PET/CT would have not been identified using other conventional morphological criteria based techniques. In Eiber et al.'s study, 68Ga-PSMA PET detected prostatic disease findings in 67% of patients with prostate-specific antigen levels <1 ng/mL, when compared with choline-based PET that presented detection rates between 19% and 36%. In Bluemel et al.'s study, 68Ga-PSMA identified positive prostatic disease in 43.8% of the patients with negative findings in F-choline PET/CT. Findings from this review demonstrate that 68Ga-PSMA PET/C is more effective in detecting metastases, lymph nodes, and recurrent prostate cancer when compared to 18F-choline-based PET/CT and CT. 68Ga-PSMA PET/CT presents also more imaging contrast and can be more cost-effective. 68Ga-PSMA has already been subjected to first-in-human trials, and it is now being tested in Phase II and III trials.

Keywords: 68 Ga-prostate-specific membrane antigen; positron emission tomography/computed tomography; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Fact Sheets by Population. [Last cited on 2016 Apr 29]. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx .
    1. RORENO – Cancer Incidence in Portugal North Region. 2015. [Last cited on 2016 Apr 29]. Available from: http://www.file:///C:/Users/Utilizador/Downloads/factsh_norte2005(4).pdf .
    1. Prostate Cancer Statistics. World Cancer Research Fund International. 2015. [Last cited on 2016 Jul 20]. Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/prost... .
    1. Globocan. Prostate Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. IARC. 2012. [Last cited on 2007 Jun 20]. Available from: http://www.globocan.iarc.fr/old/FactSheets/cancers/prostatenew.asp .
    1. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582–7. - PubMed